Trial Profile
Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Ritonavir
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Modra Pharmaceuticals
- 25 Mar 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2019.
- 02 Aug 2018 Status changed from recruiting to completed.
- 12 May 2017 Status changed from not yet recruiting to recruiting.